Solutions · For Quality and Safety

Match safety updates to products, and check reports before they go

Alerts reads PRAC outcomes and pharmacovigilance guidance against your registrations and names the products they touch. Workbench reviews a PBRER draft or a signal assessment against ICH and GVP guidance and cites what it finds.

Workbench · PBRER review

Checked against ICH E2C(R2) before sign-off

2 gaps

Adalimumab Ostra 40 mg · PBRER draft

20 sections read

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  • § 5Cumulative exposure in 5.2 differs from the summary tabulation
  • § 16A signal closed in the interval has no evaluation
  • OKInterval and data lock point consistent in every section

Alerts matched the EU strategy for ICH E2D(R1) to the same product, so the intake procedure is updated alongside the report.

The problem

Safety work arrives from two directions at once

Authority updates keep changing what has to be reported and how: a PRAC recommendation, a revised GVP module, a new ICH guideline. At the same time the team's own reports have fixed submission dates. Reading each update against the portfolio, and each draft against the guideline, is done by hand and under deadline.

Built on the source

Every line traced to its source

Answers are written from the sources retrieved for the question, not from model memory. Here is a CMC answer, claim by claim.
The answer
  1. Tightening the limit is a Type IA variation in the EU. [2]

  2. Notify within 12 months of implementing it. [1]

  3. In the US it goes in the annual report. [5]

  4. The approved limit is Q = 75% at 45 min. [D1]

Where it came from
  1. [1]
    Regulation (EC) No 1234/2008Article 8 · Type IA notifications
    EUR-Lex
  2. [2]
    Variations classification guidelineChanges to finished product specifications
    EudraLex
  3. [5]
    Changes to an approved NDA or ANDASpecifications · annual report changes
    FDA Guidance
  4. [D1]
    change-control-cc-2291.pdfPage 3 · current dissolution limit
    Your document
What it searches
  • US FDA 8
  • EU & EMA 9
  • ICH & standards 6
  • National agencies 5
  • Global regulators 4
  • Terminology 4
  • HTA bodies 3
  • Clinical & literature 2
  • Your documents
How it works

From an authority update to a checked report

Alerts names the products an update touches

Alerts matched the EU implementation strategy for ICH E2D(R1) to Adalimumab and Etanercept, whose patient support programmes do not yet use the new source classes, and proposed a procedure task for the safety lead.

Workbench maps a recommendation to your label

Workbench compares a PRAC recommendation with the approved SmPC, lists the affected sections and the wording to change, and cites both documents.

Workbench reviews the report

Workbench reads a PBRER draft and its tabulations against ICH E2C(R2). It flags missing sections, inconsistent periods or totals, and conclusions the data does not support.

In Workbench

Review a PBRER draft before sign-off

The Adalimumab Ostra 40 mg PBRER is in final draft. Workbench reads it with the summary tabulations before Rita sends it for medical sign-off.

Workbench+ New Chat
History Adalimumab PBRER review Sources
You09:14 AM

Review the attached PBRER draft and summary tabulations for Adalimumab Ostra 40 mg against ICH E2C(R2). Flag missing sections, inconsistent periods or totals, and unsupported conclusions.

adali-pbrer-draft.pdfReady
Regunaut09:14 AM
  1. understanding your question…

    Adalimumab Ostra 40 mg · EMEA/H/C/005180 · PBRER draft

Warning details⌄
  • Findings are limited to what the two documents show. The benefit-risk conclusion stays with the safety physician.

1. Short answer

Two gaps. The cumulative exposure in section 5.2 does not match the tabulation, and a signal closed during the interval has no evaluation in section 16. The reporting interval and data lock point are consistent throughout.

2. PBRER draft

SectionFinding
5.2 Cumulative exposureTotal differs from the tabulation [D2]
15 and 16 SignalsOne closed signal has no evaluation [D1]
Interval and data lock pointConsistent in all sections [D1]

3. Before sign-off

  • Reconcile the exposure total in section 5.2 with the tabulation and state the method.
  • Add the evaluation of the closed signal to section 16.
  • Send the corrected draft for medical review of the benefit-risk conclusion.
Citations (5)⌄
Helpful? Copy PDF
Example response · Condensed for this product demonstration
Ask a follow-up question...↑
In the platform today

The jobs teams run for this

Each of these is a quick task in Workbench or a tool with a screen of its own. Picking a quick task writes the prompt for you; add your product and market, and the answer comes back with its sources.

  • Workbench quick task · Drug safetyNo documents needed

    Compare safety reporting timelines

    Separate EU and US post-marketing rules from clinical-trial rules.

    See the prompt

    Compare EU and US expedited reporting requirements for post-marketing individual case safety reports for human medicines. Explain how seriousness, expectedness, case origin, and minimum case information affect reporting and the start of the clock. Distinguish these from clinical-trial reporting and cite current official guidance.

    Open Workbench
  • Workbench quick task · Drug safetyNo documents needed

    Understand RMP update triggers

    Map signal evaluation to possible risk-management actions.

    See the prompt

    Explain when new safety information may require an EU risk management plan update. Distinguish signal detection, validation, assessment, and changes to safety concerns or risk-minimisation measures. Cite current GVP guidance and describe the evidence needed for a product-specific decision.

    Open Workbench
  • Workbench quick task · Drug safetyUses your documents

    Review a signal assessment

    Identify evidence gaps and questions for further evaluation.

    See the prompt

    Review the attached anonymised aggregate safety summary and signal assessment. Identify the evidence supporting or weakening the signal, data limitations, and questions for further evaluation under applicable EU GVP guidance. Reference supplied evidence and distinguish observations from conclusions that require additional data.

    Open Workbench
  • Workbench quick task · Drug safetyUses your documents

    Review a PBRER draft

    Check completeness, consistency, and support for conclusions.

    See the prompt

    Review the attached PBRER draft and aggregate supporting tables against applicable ICH E2C(R2) guidance. Flag missing sections, inconsistent reporting periods or totals, and unsupported benefit-risk conclusions. Provide a prioritised review table with document references and distinguish gaps from items that cannot be verified.

    Open Workbench
  • Workbench quick task · LabellingUses your documents

    Assess a safety label change

    Map an authority recommendation to the affected SmPC sections.

    See the prompt

    Compare the attached approved SmPC with the attached PRAC recommendation or authority decision. Identify affected sections, proposed wording changes, and stated implementation requirements. Provide a comparison table with source references and flag ambiguities requiring regulatory review.

    Open Workbench
Why Regunaut

Safety findings you can trace

Updates read against registrations

Alerts names the product and the registration an update touches, such as EMEA/H/C/005180, and proposes one action for its owner.

Reviews tied to the guideline

Each finding in a draft review points to the section of your document and the part of ICH or GVP guidance it was checked against.

Judgement stays with the team

Workbench separates what the documents show from conclusions that need medical or regulatory review, and says which is which.

The regulation behind it

Guides and terms for this workflow

What the legislation and the agencies' guidance say, in plain language, with the sources linked.

Related on Regunaut

Run your next safety review with the guidance beside it

See Alerts and Workbench on your own products and markets in a 30-minute walkthrough.